Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLGT NASDAQ:LAB NASDAQ:MDXH NYSE:ZEPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGTFulgent Genetics$21.66-1.3%$20.68$14.57▼$22.87$662.53M0.81338,644 shs51,948 shsLABStandard BioTools$1.36-1.8%$1.31$0.92▼$2.32$517.60M1.291.67 million shs80,724 shsMDXHMDxHealth$4.35-3.4%$3.12$1.35▼$4.74$205.48M1.49100,679 shs48,743 shsZEPPZepp Health$49.27-1.2%$33.57$2.13▼$55.99$714.42M1.33291,595 shs53,739 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGTFulgent Genetics-1.44%0.00%+0.78%+12.11%+1.20%LABStandard BioTools-1.43%0.00%+8.66%+10.40%-26.20%MDXHMDxHealth-3.85%+18.42%+36.78%+101.79%+70.13%ZEPPZepp Health-3.26%+6.15%+25.33%+1,865.00%+1,472.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGTFulgent Genetics$21.66-1.3%$20.68$14.57▼$22.87$662.53M0.81338,644 shs51,948 shsLABStandard BioTools$1.36-1.8%$1.31$0.92▼$2.32$517.60M1.291.67 million shs80,724 shsMDXHMDxHealth$4.35-3.4%$3.12$1.35▼$4.74$205.48M1.49100,679 shs48,743 shsZEPPZepp Health$49.27-1.2%$33.57$2.13▼$55.99$714.42M1.33291,595 shs53,739 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGTFulgent Genetics-1.44%0.00%+0.78%+12.11%+1.20%LABStandard BioTools-1.43%0.00%+8.66%+10.40%-26.20%MDXHMDxHealth-3.85%+18.42%+36.78%+101.79%+70.13%ZEPPZepp Health-3.26%+6.15%+25.33%+1,865.00%+1,472.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLGTFulgent Genetics 2.67Moderate Buy$25.3316.99% UpsideLABStandard BioTools 2.00Hold$1.5514.39% UpsideMDXHMDxHealth 3.00Buy$7.0061.10% UpsideZEPPZepp Health 3.00Buy$60.2322.24% UpsideCurrent Analyst Ratings BreakdownLatest MDXH, ZEPP, FLGT, and LAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025ZEPPZepp HealthFundamental ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$60.238/13/2025LABStandard BioToolsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold8/13/2025LABStandard BioToolsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$1.558/5/2025FLGTFulgent GeneticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$20.00 ➝ $30.008/4/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$23.00 ➝ $21.007/17/2025LABStandard BioToolsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2025MDXHMDxHealthCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.00(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLGTFulgent Genetics$303.22M2.19N/AN/A$36.92 per share0.59LABStandard BioTools$174.43M2.97N/AN/A$1.27 per share1.07MDXHMDxHealth$90.05M2.28N/AN/A$0.31 per share14.02ZEPPZepp Health$182.60M3.91N/AN/A$17.43 per share2.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLGTFulgent Genetics-$42.71M-$1.66N/AN/AN/A-16.83%-2.26%-2.10%11/14/2025 (Estimated)LABStandard BioTools-$138.88M-$0.32N/AN/AN/A-69.08%-20.23%-15.32%10/29/2025 (Estimated)MDXHMDxHealth-$38.07M-$0.88N/AN/AN/A-34.98%-374.98%-21.97%11/5/2025 (Estimated)ZEPPZepp Health-$75.73M-$4.83N/A∞N/A-38.81%-24.19%-11.36%11/17/2025 (Estimated)Latest MDXH, ZEPP, FLGT, and LAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025MDXHMDxHealth-$0.13-$0.15-$0.02-$0.15$26.60 million$26.60 million8/1/2025Q2 2025FLGTFulgent Genetics-$0.23$0.07+$0.30-$0.62$76.21 million$81.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLGTFulgent GeneticsN/AN/AN/AN/AN/ALABStandard BioToolsN/AN/AN/AN/AN/AMDXHMDxHealthN/AN/AN/AN/AN/AZEPPZepp HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLGTFulgent GeneticsN/A6.016.01LABStandard BioToolsN/A5.164.92MDXHMDxHealth13.811.311.22ZEPPZepp Health0.311.100.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLGTFulgent Genetics48.06%LABStandard BioTools53.74%MDXHMDxHealthN/AZEPPZepp Health52.61%Insider OwnershipCompanyInsider OwnershipFLGTFulgent Genetics33.11%LABStandard BioTools23.16%MDXHMDxHealth1.70%ZEPPZepp Health36.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLGTFulgent Genetics1,31330.61 million20.47 millionOptionableLABStandard BioTools620381.99 million293.53 millionOptionableMDXHMDxHealth30047.29 million46.48 millionNot OptionableZEPPZepp Health1,23014.50 million9.28 millionOptionableMDXH, ZEPP, FLGT, and LAB HeadlinesRecent News About These CompaniesZepp Health (NYSE:ZEPP) Trading Down 3.5% - Here's What HappenedSeptember 23 at 3:44 PM | marketbeat.comAmazfit Helio Strap review: A true Whoop challengerSeptember 17, 2025 | wareable.comWShort Interest in Zepp Health Corporation Sponsored ADR (NYSE:ZEPP) Rises By 30.0%September 17, 2025 | marketbeat.comZepp Health (NYSE:ZEPP) Shares Gap Down - Should You Sell?September 14, 2025 | marketbeat.comZepp Health (NYSE:ZEPP) Shares Gap Down - Here's What HappenedSeptember 14, 2025 | americanbankingnews.comZepp Health (NYSE:ZEPP) Trading Down 6.5% - Time to Sell?September 13, 2025 | marketbeat.comAmazfit Announces Olympic Medalist Grant Fisher as New Brand AmbassadorSeptember 11, 2025 | prnewswire.comAmazfit Launches T-Rex 3 Pro Smartwatch, Featuring a Rugged Titanium Design and Integrated FlashlightSeptember 7, 2025 | finanznachrichten.deZepp Health acquiert les actifs principaux de Wild.AI afin d’étendre son soutien aux athlètes féminines à toutes les étapes de leur vieSeptember 6, 2025 | joplinglobe.comJThe Amazfit T-Rex 3 Pro is the cheap Garmin Fenix 8 Pro alternative I've been looking forSeptember 6, 2025 | msn.comZepp Health adquire ativos essenciais da Wild.AI para ampliar o suporte a atletas femininas em todas as etapas da vidaSeptember 6, 2025 | bakersfield.comBZepp Health erwirbt Kern-Assets von Wild.AI, um die Unterstützung von Sportlerinnen in allen Lebensphasen auszubauenSeptember 5, 2025 | eagletribune.comEZepp Health compra los activos principales de Wild.AI para brindarles más apoyo a las atletas en todas las etapas de la vidaSeptember 5, 2025 | eagletribune.comEAmazfit Ambassador Ruth Croft Claims Victory at the 2025 UTMBSeptember 5, 2025 | businesswire.comAmazfit T-Rex 3 Pro Smartwatch Launches Featuring a Rugged Titanium Design and Integrated FlashlightSeptember 5, 2025 | businesswire.comZepp Health acquires core assets of Wild.AI, terms not disclosedSeptember 5, 2025 | msn.comZepp Health Acquires Wild.AISeptember 4, 2025 | marketwatch.comZepp Health Acquires Core Assets of Wild.AI to Expand Support for Female Athletes Across Life StagesSeptember 4, 2025 | businesswire.comZepp Health (NYSE:ZEPP) Sets New 12-Month High - Should You Buy?September 4, 2025 | marketbeat.comZepp Health (NYSE:ZEPP) Sees Strong Trading Volume - Should You Buy?August 27, 2025 | marketbeat.comPetra Industries Partners With Zepp Clarity To Provide High-Quality Hearing AidsAugust 8, 2025 | twice.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDXH, ZEPP, FLGT, and LAB Company DescriptionsFulgent Genetics NASDAQ:FLGT$21.66 -0.29 (-1.30%) As of 11:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Standard BioTools NASDAQ:LAB$1.36 -0.03 (-1.81%) As of 11:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.MDxHealth NASDAQ:MDXH$4.34 -0.16 (-3.44%) As of 11:12 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.Zepp Health NYSE:ZEPP$49.27 -0.61 (-1.22%) As of 11:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zepp Health Corporation operates as a smart wearable and health technology company worldwide. The company operates in two segments: Self-Branded Products and Others, and Xiaomi Wearable Products. It empowers users to live lives by optimizing health, fitness, and wellness journeys through its consumer brands, Amazfit, Zepp Clarity, and Zepp Aura. The company through its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors, and data algorithms, delivers cloud-based 24/7 actionable insights and guidance to help users attain wellness goals. The company offers smart bands, watches, modules, and scales; and associated accessories, smart hearable products, sportswear, home fitness equipment, home appliances, and smart watch accessories. It also provides charts and graphs to display analysis of the activity and biometric data collected from users through its Zepp Life and Zepp mobile apps. It offers its products under the Amazfit and Zepp brand names in approximately 90 countries. The company was formerly known as Huami Corporation and changed its name to Zepp Health Corporation in February 2021. Zepp Health Corporation was founded in 2013 and is headquartered in Hefei, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm’s RSI Just Hit Its High of the Year—Why That’s Bullish 2 Ways to Trade Amazon Ahead of October’s Prime Day AutoZone Pulls Into a Buy-the-Dip Opportunity Rocket Lab’s Bullish Case Remains Intact Despite Recent Offering Broadcom Price Targets Just Reached Above $400 for the First Time These 3 Mega-Cap Giants Just Increased Dividends by 7% or More 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
